Clinical trials: Head and Neck Cancer Patients
Squamous Cell Carcinoma of the Head and Neck
Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT03855384
- Testing
- TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
- Where
- China
- Volunteers
- 334 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Trial name
- NCT06273852
- Testing
- PBA-0405
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pure Biologics S.A.
Esophageal Squamous Cell Carcinoma
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
This trial is a registrational Phase II/III, randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with tislelizumab ± 5-FU in patients with unresectable, locally…
- Trial name
- NCT07554456
- Testing
- BL-B01D1, Tislelizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC
- Trial name
- NCT04799054
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 188 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Stomach Neoplasm, Gastrointestinal Neoplasms
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Our main objective is to evaluate the effect of Ocoxin-Viusid on the quality of life of patients with advanced stomach cancer and esophagogastric junction.
- Conditions
- Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Esophageal Neoplasms
- Trial name
- NCT03549494
- Testing
- Ocoxin-Viusid®
- Where
- Cuba
- Volunteers
- 45 people
- Sponsor
- Catalysis SL
Maligant Solid Tumor, Head & Neck Cancer
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Conditions
- Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
- Trial name
- NCT07459283
- Testing
- INN805
- Where
- China
- Volunteers
- 10 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or…
- Conditions
- Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
- Trial name
- AHEAD-MERIT (NCT04534205)
- Testing
- BNT113, Pembrolizumab
- Where
- 138 sites in United States, Argentina and 19 more
- Volunteers
- 358 people
- Sponsor
- BioNTech SE
Head and Neck Cancer
A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma
This open-label study will assess the pharmacodynamics, safety and efficacy of RO5083945 as compared to cetuximab in patients with head and neck squamous cell carcinoma.
- Trial name
- NCT01046266
- Testing
- RO5083945, cetuximab
- Where
- 7 sites in France, Italy and 3 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Prostate Cancers, Breast Cancer
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings.
- Conditions
- Prostate Cancers, Breast Cancer, Head and Neck Cancer, Cancer
- Trial name
- PETRiS (NCT06970275)
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 850 people
- Sponsor
- XEOS Medical
Radiodermatitis, Quality of Life
Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®
To evaluate the performance of Xonrid® in the prevention and treatment of G2 radiation dermatitis in breast and head \& neck cancer patients.
- Trial name
- NCT03255980
- Testing
- Xonrid® gel, Standard of Care
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Helsinn Healthcare SA
Carcinoma, Non-Small-Cell Lung, Melanoma
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03891953
- Testing
- DKY709, PDR001
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Tumors, Solid Tumors
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors
This is an open-label, multicenter, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 Bispecific Antibody Injection in patients with…
- Trial name
- NCT07763639
- Testing
- SI-B036
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Genmab
Nasopharyngeal Carcinoma
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
This is an open label, single-arm, multi-center, phase 2 Study of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma(R/M NPC) patients who have received previous at least two lines of chemotherapy.
- Trial name
- NCT03558191
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Adult Solid Tumor
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in…
- Trial name
- NCT04892043
- Testing
- SQZ-AAC-HPV, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- SQZ Biotechnologies
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of DM005 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
- Trial name
- NCT06515990
- Testing
- DM005
- Where
- 6 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Doma Biopharmaceutical（Suzhou）Co., Ltd.
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Head Cancer Neck
Evaluation of Oncoxin-Viusid® in Head and Neck Cancer
Nutritional supplements containing antioxidants seem to decrease toxicity associated with Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors.
- Trial name
- NCT03541772
- Testing
- Oncoxin-Viusid®
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL